Gutierrez-Baños J, Portillo J, Ballestero R, Zubillaga S, Ramos E, Campos J, Hidalgo E
Department of Urology, University Hospital Valdecilla, Santander, Spain.
Transplant Proc. 2008 Dec;40(10):3424-7. doi: 10.1016/j.transproceed.2008.06.111.
We report the renal graft outcomes among a series of patients who underwent simultaneous combined liver-kidney transplantations (CLKT) or heart-kidney transplantations (CHKT) at a single center.
From 1975 to December 31, 2007, we performed 1524 kidney transplantations, 427 liver transplantations, and 483 heart transplantations, including 7 simultaneous CLKT and 2 CHKT. We analysed the main patient characteristics, renal graft outcomes, and patient survivals.
CLKT indications were as follows: alcoholic cirrhosis (n = 5) and hepatitis C virus (n = 2) with chronic glomerulonephritis (n = 5), hypertensive nephropathy (n = 1), and polycystic disease (n = 1). Cold renal ischemia time was 6.9 hours (range, 6-9). In 5 patients there were no kidney rejection episodes; 3 of these patients are alive with creatinine levels between 1.4 and 1.7 mg/dL with an average follow-up of 6.9 years (range, 10 months-8 years). One patient died of esophageal cancer at 13 years after transplantation with a serum creatinine level of 1.16 mg/dL and another died of breast cancer at 7 years after transplantation with a creatinine level of 1.1 mg/dL. One patient lost his renal graft just after the kidney transplantation due to renal vein thrombosis. The last patient suffered 1 episode of acute rejection and lost his kidney 5 years later due to chronic rejection. CHKT indications were as follow: dilated myocardiopathy (n = 2) and chronic glomerulonephritis (n = 1) or interstitial nephropathy (n = 1). The cold renal ischemia time was 4 hours. There were no acute rejection episodes. One patient is alive with a creatinine level of 2.05 mg/dL at 6 years after the transplantation; the other patient lost his kidney due to chronic rejection at 270 days after simultaneous CHKT, and 2 years later received a second kidney that is functioning normally.
Simultaneous CLKT and CHKT in selected cases provided satisfactory long-term outcomes in both graft function and patient survival with lesser number of acute rejection episodes than nonsimultaneous transplantations. They are worthy options for patients with liver or heart failure associated with renal failure.
我们报告了在单一中心接受同期肝肾联合移植(CLKT)或心肺联合移植(CHKT)的一系列患者的肾移植结果。
从1975年至2007年12月31日,我们进行了1524例肾移植、427例肝移植和483例心脏移植,其中包括7例同期CLKT和2例CHKT。我们分析了主要患者特征、肾移植结果和患者生存率。
CLKT的适应证如下:酒精性肝硬化(n = 5)、丙型肝炎病毒(n = 2)合并慢性肾小球肾炎(n = 5)、高血压肾病(n = 1)和多囊肾病(n = 1)。冷缺血时间为6.9小时(范围6 - 9小时)。5例患者未发生肾排斥反应;其中3例患者存活,肌酐水平在1.4至1.7mg/dL之间,平均随访6.9年(范围10个月 - 8年)。1例患者在移植后13年死于食管癌,血清肌酐水平为1.16mg/dL,另1例在移植后7年死于乳腺癌,肌酐水平为1.1mg/dL。1例患者在肾移植后因肾静脉血栓形成而失去肾移植。最后1例患者发生1次急性排斥反应,5年后因慢性排斥反应失去肾脏。CHKT的适应证如下:扩张型心肌病(n = 2)、慢性肾小球肾炎(n = 1)或间质性肾病(n = 1)。冷缺血时间为4小时。未发生急性排斥反应。1例患者在移植后6年存活,肌酐水平为2.05mg/dL;另1例患者在同期CHKT后270天因慢性排斥反应失去肾脏,2年后接受了第二个功能正常的肾脏。
在选定病例中,同期CLKT和CHKT在移植肾功能和患者生存率方面均提供了令人满意的长期结果,急性排斥反应发作次数少于非同期移植。对于合并肾衰竭的肝或心力衰竭患者,它们是值得选择的方案。